MacroGenics Files 8-K Report

Ticker: MGNX · Form: 8-K · Filed: 2025-08-14T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, routine-update

Related Tickers: MGNX

TL;DR

MGNX filed a routine 8-K, no major news, just confirming address.

AI Summary

On August 14, 2025, MacroGenics, Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and does not disclose specific financial results or material events as of this date. The report confirms the company's principal executive offices are located at 9704 Medical Center Drive, Rockville, Maryland, 20850.

Why It Matters

This 8-K filing is a routine disclosure that confirms the company's operational details and registered information with the SEC, providing transparency for investors.

Risk Assessment

Risk Level: low — This filing is a standard procedural update and does not contain information that would immediately impact the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by MacroGenics, Inc.?

The primary purpose of this 8-K filing is to serve as a current report, indicating the date of the earliest event reported as August 14, 2025, and confirming the company's registered information.

When was this 8-K report filed?

This 8-K report was filed as of August 14, 2025.

What are the principal executive offices of MacroGenics, Inc.?

The principal executive offices of MacroGenics, Inc. are located at 9704 Medical Center Drive, Rockville, Maryland, 20850.

What is the trading symbol for MacroGenics, Inc. common stock and on which exchange is it listed?

The trading symbol for MacroGenics, Inc. common stock is MGNX, and it is registered on the Nasdaq Global Select Market.

Does this 8-K filing disclose any specific financial results or material events?

Based on the provided text, this 8-K filing does not disclose specific financial results or material events; it primarily serves as a notification of the company's status and registered information.

Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-08-14 16:04:17

Key Financial Figures

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition On August 14, 2025, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release dated August 14, 2025 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 2025 MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel

View on Read The Filing